ITM has identified, selected and exclusively focused on the development and optimization of such radio-isotope based therapies, which already had a promising, developing medical track-record and showed a unique effectiveness, especially in patients who had either run out of established, conventional treatment options - or who were otherwise even considered untreatable and thereby reduced to expensive palliative care.

The risks of validating basic clinical and economical effectiveness of these treatments were therefore already largely absorbed, so that itm could immediately concentrate on the industrialization of the supply-chain and focus investments on the optimization of processes and application systems.

• ITM Rhenium-SCT: The New Generation of Non-Invasive Skin Cancer Therapy

• ITM Rhenium-PTA/PTCA: The New Generation of Endovascular Brachytherapy

• PRRT: Peptide Receptor Radioisotope Therapies: The New Approach to Personalized Medicine

For further information concerning specialized medical applications please select the appropriate Link below:

• Oncology
• Personalized Medicine
• Dermatology
• Radiology
• Cardiology